All news

A 753-share sale covers stock-vesting taxes at Relay Therapeutics (RLAY).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics (RLAY), sold 753 shares of common stock at

Read original source

RLAY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.